ArticleNoro psikiyatri arsivi2026
Tonsillar Alpha-Synuclein Accumulation on Parkinson's Disease.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Parkinson's disease (PD) is a neurodegenerative disorder caused by the misfolding of alpha-synuclein (α-synuclein) proteins. Despite treatment, misdiagnosis rates can reach up to 50% within the first five years, highlighting the need for reliable biomarkers. However, the presence and role of α-synuclein in lymphatic tissues, such as the tonsils, have not been adequately investigated. The tonsils are accessible lymphatic organs that may serve as potential sites for α-synuclein accumulation due to their rich innervation and immune activity. Therefore, this study aims to investigate and compare α-synuclein levels in the tonsillar tissues of patients with Parkinson's disease and healthy controls. By evaluating the tonsils as a potential site of α-synuclein deposition, this study aims to explore their role as a possible biomarker. Methods: After ethical approval, participants were selected from Neurology Outpatient Clinic diagnosed with idiopathic Parkinson's per UK Parkinson's Disease Society Brain Bank Criteria. The control group comprised individuals undergoing tonsillectomy with no neurological symptoms. We collected and analyzed tonsil tissues from 15 control and 11 PD patients using ELISA to determine α-synuclein concentrations. Data were analyzed using IBM SPSS 25.0, employing Mann-Whitney U and Kolmogorov-Smirnov tests to evaluate differences in α-synuclein levels, with significance set at p<0.05. Results: No significant age or gender differences were noted between groups. PD patients showed higher α-synuclein concentrations in tonsillar tissues compared to controls, with statistical significance. Discussion: Our results suggest that tonsillar tissue could serve as a novel peripheral biomarker, potentially reflecting α-synuclein accumulation in PD. Future studies are needed to clarify the underlying mechanism of α-synuclein deposition in tonsils, its correlation with disease severity and progression and its potential role in monitoring treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.